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Abstract 
Introduction: Kidney function is reported using estimates of glomerular filtration rate 
(eGFR).  However, eGFR values are recorded without reference to the creatinine (SCr) assays 
used to derive them, and newer assays were introduced at different time points across 
laboratories in UK. These changes may cause systematic bias in eGFR reported in routinely 
collected data; even though laboratory reported eGFR values have a correction factor 
applied. 
 
Design: An algorithm to detect changes in SCr which affect eGFR calculation method by 
comparing the mapping of SCr values on to eGFR values across a time-series of paired eGFR 
and SCr measurements.  
 
Setting: Routinely collected primary care data from 20,000 people with the richest renal 
function data from the Quality Improvement in Chronic Kidney Disease (QICKD) trial. 
 
Results: The algorithm identified a change in eGFR calculation method in 80 (63%) of the 
127 included practices. This change was identified in 4,736 (23.7%) patient time series 
analysed. This change in calibration method was found to cause a significant step change in 
reported eGFR values producing a systematic bias. eGFR values could not be recalibrated by 
applying the Modification of Diet in Renal Disease (MDRD) equation to the laboratory 
reported SCr values. 
 
Conclusions: This algorithm can identify laboratory changes in eGFR calculation methods 
and changes in SCr assay. Failure to account for these changes may misconstrue renal 
function changes over time. Researchers using routine eGFR data should account for these 
effects. 
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Introduction 
Chronic kidney disease (CKD) is a significant public health problem and is becoming more 
common with an aging population and increasing disease burden from diabetes (1, 2). There 
is a complex relationship between CKD, diabetes, and hypertension resulting in increased 
risk of mortality and cardiovascular disease in people with these commonly co-morbid 
conditions (3). Recent estimates of the prevalence of CKD in the UK are around 7.3-8.5% (4, 
5). This is associated with substantial financial burden: In 2009-2010 the cost of CKD to the 
English NHS was estimated at £1.44-£1.45 billion, approximately 1.3% of the total NHS 
spending during this period (6). Over half of this was spent on renal replacement therapy for 
people with end stage renal disease (ESDR), which accounts for only 2% of the CKD 
population (6). Early identification, appropriate referral, and intervention in CKD are 
therefore critically important. 
 
Estimation of renal function has been routine in clinical practice since the publication of the 
Cockcroft-Gault equation for estimating creatinine clearance in 1976 (7). Categorisation of 
CKD and clinical decisions are currently based on estimated glomerular filtration rate (eGFR) 
(8, 9) although the Cockcroft-Gault equation is still widely used to calculate drug dosing (10, 
11). eGFR can be calculated from serum creatinine (SCr) measurements using the 
Modification of Diet in Renal Disease (MDRD) equation first published in 1999 (12) and later 
simplified in 2003 (13). However, the MDRD equation underestimates GFR in people with 
mild renal impairment (14, 15) and in some subgroups such as kidney donors and people 
with diabetes (16, 17). More recently the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation was developed to tackle these limitations and has been 
demonstrated to have improved performance in mild renal impairment and across patient 
subgroups (18-21).  
 
Continuously changing methods for calculating renal function present a problem for both 
clinicians and researchers. Changing methods of eGFR calculation affect trends in renal 
function over a period of years. This problem is further compounded by differing creatinine 
assays between laboratories (22, 23). The UK National External Quality Assessment Scheme 
(UKNEQAS) recommend each clinical laboratory calculate eGFR from an isotope dilution 
mass spectrometry (IDMS) creatinine assay; a standardisation program which was initiated 
in 2007 (24, 25) with different laboratories achieving standardisation at different times. In 
clinical practice, laboratory calculated eGFR values are reported without reference to the 
equations or creatinine assays that were used to derive them.  Records will also contain 
eGFR results derived in practice possibly using one of the many online calculators.  This 
practice was very common when primary care first became aware of CKD (26). 
 
Before the introduction of the MDRD equation there was no reported eGFR. Following the 
introduction of this equation laboratories were reporting eGFR calculated from various 
inhomogeneous creatinine assays. These were then phased out to be replaced by a 
standardised method based on the IDMS assay (Figure 1). 
 
 
Figure 1:  Changes in reporting of serum creatinine and eGFR data over time. Since the 
1990’s, various versions of serum creatinine measurements have been systematically 
recorded. Since 2006, eGFR has been used. Between 2006 and 2009, creatinine assays have 
been standardised and correction factors applied before using the MDRD have changed with 
the assay method. 
 
Current clinical guidelines recommend early referral of patients with declining GFR to 
specialist services. Whilst standardisation of current eGFR values has been achieved there is 
a need for retrospective calibration both in the research and clinical settings to allow 
accurate monitoring of renal function trends. The previous existence of these 
heterogeneous assays prevents accurate assessment of trends in retrospective data because 
these assays are incompatible with each other. Should the CKD-EPI equation be widely 
adopted in primary care this will be of renewed importance (27). Here we devise a method 
for identifying changes in eGFR calculation method (which includes correction factors for 
the creatinine assay used) in routinely collected data. Identification of these changes in 
eGFR calculation method is the first step towards backwards calibration of the entire eGFR 
time-series for a given patient – i.e. making all of the patient’s eGFR measurements 
compatible. Without such a method trends in renal function are misleading. Our algorithm 
identifies the date of change from one method eGFR calculation method to the next for 
each patient and primary care practice. 
Method 
The UK electronic patient record is currently coded using the Read coding system. This 
enables coding of the eGFR equation used, although eGFR can be coded with no reference 
to the equation used. We investigated the range of codes available to record eGFR to 
explore if there was scope to improve the provenance of these data.  
 
We devised an algorithm which is able to identify the changes in calculation method of eGFR 
for any time series of eGFR and SCr measurements for a given patient. This method requires 
a time series of paired eGFR and SCr values for each patient i.e. SCr and eGFR values 
measured simultaneously. We shall call this paired measurement time series the renal 
function time series of the patient. 
The eGFR method change finding algorithm 
Each laboratory uses a function (Mlab) to convert SCr measurements (c) into eGFR values 
(glab). Thus: 
 
),( CFcMg lablab       (1) 
where CF represents patient-specific adjustment based on patient characteristics (age, 
gender, and ethnicity). To identify changes in Mlab we defined a self-calculated eGFR (gself) 
generated using the MDRD equation (MMDRD) and using patient characteristics (CF) taken 
from the patient record: 
 
),( CFcMg MDRDself       (2) 
We then defined a mapping function (Mu) which maps the self-calculated eGFR onto the lab 
calculated eGFR (Figure 2). The lab calculated eGFR can therefore also be written as: 
 
)( selfulab gMg       (3) 
The mapping function Mu will vary with the laboratory eGFR calculation function, Mlab. It is 
therefore possible to determine the number of laboratory Mlab functions by determining 
how many Mu functions are required to map the entire renal function time series. We 
identified that Mu is a linear function in the logarithmic domain of its argument, glab and gself. 
Let us define the mapping function from log(glab) to log(gself) be Mu′. This function must be 
linear1, taking the form of: 
 01
)log())(log(' wgwgM selflabu     (4) 
where the parameters w1 and w0 can be found by the method of least square regression in 
the case of a single assay method and a mixture of regression (28) in the case of multiple 
assay methods. The lab calculated eGFR can therefore be obtained by:  
 
))log(exp()( 01 wgwgMg selfselfulab    (5) 
Performing this mapping from gself onto glab for a series of two or more measurements 
enables w1 and w0 to be calculated. The number of w1 and w0 value pairs required to map a 
renal function time series for a given patient is the number of laboratory eGFR calculation 
functions used. 
 
 
Figure 2: The relationship between different variables. gself refers to self-calculated eGFR 
using the MDRD; glab, the lab calculated eGFR; c, serum creatinine; M, different mapping 
functions. Both the MMDRD and Mlab also use ethnicity, age, and gender of the patient (not 
shown here).  
                                                     
1
 The proof is omitted but can be easily deduced from MDRD equations in the log domain. 
Subjects and setting 
We generated and tested the algorithm using anonymised patient records collected from 
127 primary care practices across England; a total of nearly a million patient records 
(n=951,764). This data was obtained for the Quality Intervention in Chronic Kidney Disease 
(QICKD) trial (clinical trials registration: ISRCTN56023731) (4). These primary care samples 
comprise a nationally representative sample of urban, sub-urban and rural practices in 
localities within London, Surrey, Sussex, Leicester, Birmingham and Cambridge. The 
complete protocol used for sampling and data collection from these practices for the QICKD 
trial have been previously described (29). In brief, routine clinical records were collected 
between June 2008 and December 2010. All practices had a final data collection in 
December 2010. All patients registered with the included practices at the time of the first 
the sampling period (June 2008) were included in the data sample. Complete historical 
records were obtained for all these patients for a number of clinical variables including data 
relating to renal function. All data was anonymised at the point of data extraction. Data 
from each practice was labelled with an anonymised practice ID number. 
 
To analyse the usage of eGFR codes we counted the total number of eGFR codes used in the 
primary care records of all 951,764 people included in the QICKD database.  
 
To test our eGFR calculation change finding algorithm we selected 20,000 patients with the 
most complete renal function time series in terms of the number of paired laboratory eGFR 
and SCr.  
 
From the initial patient set, we excluded lab reported values of eGFR readings exactly equal 
to 60 or 90 ml/min because these values correspond to the capped thresholds chosen by 
certain laboratories. For example an eGFR value of 93 ml/min, in some cases, are recorded 
as 60 ml/min by laboratories which adopt the threshold of 60 ml/min or 90 ml/min for 
others which adopt the higher threshold. 
 
We also used an anonymised practice identification number to group patients by practice. 
We used this to calculate a time interval between which each practice changed its’ eGFR 
calculation method. As all practices sent laboratory samples to a single laboratory this 
change will affect all eGFR measurements reported by that practice. The latest identified 
measurement of the first calculation method and the earliest identified measurement of the 
second method in each practice were used to define the interval in which the change in 
method occurred. 
Ethical considerations 
No patient identifiable data was used in the analysis presented here. All data was 
anonymised at the point of data extraction. The original QICKD study was approved by the 
Oxford Research Ethics Committee (Committee C). This ethics approval included 
authorisation for secondary analysis of the QICKD dataset. 
Results 
A total of 1,309,337 unique eGFR measurements were identified in the QICKD database. The 
majority (98.7%) of eGFR values were recorded using an equation specific code (Table 1). No 
codes were identified in the Read code system which enable recording of creatinine assay 
method. 
 
Read 
Code 
Code description Number recorded (%) 
451F. Glomerular filtration rate 16,317 (1.2%) 
451E. Glomerular filtration rate calculated by abbreviated Modification of 
Diet in Renal Disease Study Group calculation 
1,292,572 (98.7%) 
451G. Glomerular filtration rate calculated by abbreviated Modification of 
Diet in Renal Disease Study Group calculation adjusted for African 
American origin 
448 (0.04%) 
451K. Estimated glomerular filtration rate using Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula 
0 (0.0%) 
Table 1. The abundance of 5 byte version 2 Read codes for recording eGFR in the primary 
care records of 951,764 people. Note the CKD-EPI Read code was not available at the time 
these data were recorded. Total  
 
The 951,764 patient records obtained from QICKD trial database were available for analysis. 
For this study, we used the top 20,000 patients who have the renal function time series with 
the highest number of paired eGFR and SCr values. These 20,000 people included had a 
median age of 74 (interquartile range; IQR 64 to 81). 10,931 (54.7%) people were female. 
The median number of SCr measurements per person was 22 (IQR 19 to 28) and the median 
number of eGFR measurements 16 (IQR 13 to 20). 13,563 (67.8%) people had five or more 
SCr and lab calculated eGFR values recorded simultaneously. 
 
4,736 (23.7%) people had two distinct detectable methods of calculation of eGFR from SCr. 
These methods always occurred sequentially with laboratories converting from one method 
to the other. We did not identify any patients with more than two methods of calculating 
eGFR.  
 
By grouping patients by their anonymised practice ID we identified the range of dates 
between which the change in eGFR calculation method occurred for each practice (Figure 
3). We identified a change in method in 80 (63%) of 127 included practices. 
 
Figure 3: The estimated dates of eGFR calculation method change for each practice where a 
change was detected in one or more patients within the practice. The range of uncertainty is 
shown for each practice using a horizontal line. 
 
eGFR time series from patients who had stable renal function both before and after the 
change in laboratory eGFR calculation method demonstrate a substantial step change at the 
time of the change in method (Figure 4). Using the MDRD to calculate eGFR from the 
reported SCr measurements similarly demonstrates a discontinuity (Figure 5).  Almost all of 
the step changes were an improvement in renal function. All of these changes occurred 
exactly at the time of change in eGFR calculation method. Both of these factors make this 
observation highly unlikely to be due to an actual physiological change in these patients. 
 
 
Figure 4: Two examples of selected patients with stable renal function. The change in eGFR 
calculation method (vertical line) can be seen to coincide with a step discontinuity in eGFR 
values. 
 
 
 
Figure 5: Attempted back calibration by applying the MDRD to the lab reported creatinine 
values. Recalibration reduces the apparent step discontinuity in these patients compared to 
the lab reported eGFR values (grey) but a considerable discrepancy is still evident. The 
patients shown are the same as in Figure 4. 
Discussion 
Principal findings  
Our algorithm is able to detect changes in eGFR calculation method from a time-series of 
eGFR and SCr measurements for any given patient. This change was detected in 23.7% of 
the people with the highest number of recorded renal function measurements. From these 
data we identified a change in eGFR calculation method in 63% of the included practices 
which occurred between January 2006 and December 2010. There were no practices with 
more than two eGFR calculation methods identified. 
 
Changes in eGFR calculation method create a substantial spurious step change in patient’s 
renal function at the time of change in method. Recalculating eGFR from SCr measurements 
does not remove this spurious step change. This suggests that the change in eGFR 
calculation method is also associated with a change in creatinine assay. This is consistent 
with laboratories responding to the UKNEQAS recommendations to standardise to use the 
IDMS creatinine assay (25). 
 
The type of equation used to calculate eGFR was generally well recorded but there is 
currently no way of recording the creatinine method using the Read code system. 
Implications of the findings 
Both clinical decisions, such as when to refer to specialist services (8, 9), are often based on 
renal function trends. Furthermore, there is an increasing amount of research utilising 
routinely collected data. We have demonstrated that over a third of renal function time 
series are subject to spurious step changes in renal function as a result of changes in 
laboratory eGFR calculation methods and creatinine assay changes. If these artefactual 
changes in renal function are not taken into account in research or clinical decisions utilising 
longitudinal data of this type there is substantial potential for systematic error. 
 
If information on the type of equation and creatinine assay was required by the eGFR coding 
structure these artefactual changes would be easy to identify and correct. However whilst 
the current primary care coding system in the UK (Read codes) does allow this data to 
recorded this is rarely used. Future recording of eGFR should make use of such features to 
maximise the clinical and research utility of eGFR measurement and prevent spurious data 
from impacting on patient care. 
Comparison with the literature  
To our best knowledge there have been no previous attempts to detect the time series 
artefacts we report using large scale population data. The high level of background noise in 
eGFR measurements (30) mean that these artefacts are not easily identified when observing 
the data using standard methods. 
 
The importance of coding the context of blood glucose measurements has been previously 
noted although this call to improve standards has gone unheeded (31). Recording the 
context of eGFR measurements presents a similar problem. To effectively tackle this issue 
may require a change in the coding structure of existing coding systems. 
Limitations of the method 
The algorithm requires a minimum of two paired eGFR and SCr measurements before a 
change in eGFR calculation method and two after to correctly identify the change. This limits 
the population to which the method can be applied. However in dataset where additional 
information is known, such as the hospital or primary care centre where the test was 
performed, data from a few patients with a complete renal function time series can be used 
to predict eGFR calculation method changes in the rest of the population. 
 
Additionally, this method cannot be applied to people with normal renal function as their 
exact eGFR values are not reported (reported as either >60 ml/min or >90 ml/min). In 
practices where a change in eGFR calculation method has been detected this change can be 
assumed affect all members of that practice and could be used to calibrate these data. 
Furthermore, the exact value of eGFR for this population is of less importance given the 
poor reliability of eGFR in people with good renal function. 
 
The data used here is now over four years old limiting the clinical utility of this method. 
However this method is still important for research using longitudinal data. Additionally, as 
laboratories change from using the MDRD equation to the CKD-EPI equation there will be 
another period of laboratory eGFR calculation changes. Detection and elimination of the 
artefacts generated by this new change will be important both clinically and for future 
epidemiological research with a focus on renal function. 
Call for further research  
Our method is the first step to generating a back calibration algorithm which can correct for 
the different eGFR calculation methods used by different laboratories. Although direct 
application of the MDRD equation (or other equations) to recorded SCr measurements does 
not correct the measurements (primary due to changes in creatinine assays used) this does 
not preclude the possibility of successfully calibrating these data. 
Conclusions 
This algorithm can identify laboratory changes in eGFR calculation methods. Failure to 
identify these changes in method may cause misclassification of CKD and misconstrue renal 
function changes over time. Whilst there is scope to improve clinical coding this can only be 
prospective, and flagging the limitations of data at the time is important for future 
researchers if they are to derive most meaning from these data.  Researchers using 
longitudinal routinely collected renal function data should account for these effects. 
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